Clinical trials for medicines: Good clinical practice inspections

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) enforces clinical trial standards based on the ICH E6 (R3) Good Clinical Practice (GCP) framework. This guidance applies to pharmaceutical companies, research organizations, hospitals, and laboratories to ensure ethical conduct and data integrity. The MHRA performs risk-based, systems-based, and trial-specific inspections, grading deficiencies as critical, major, or other. Critical findings include risks to patient safety, unreliable data, or obstructing access to the Trial Master File. Recent enforcement actions include an infringement notice issued to Celixir in July 2024 for non-compliance with trial authorizations and investigational dossiers, requiring comprehensive corrective actions and independent auditing. Past cases from 2016 and 2017 involving Dr. David Connell, Mrs. Zirka Yousaf, and Dr. Jerome Kerrane highlighted issues such as unauthorized subcontracting, poor documentation, and protocol deviations. Organizations are required to report serious breaches, provide full digital and physical record access, and submit Corrective and Preventative Action (CAPA) plans following inspections. Severe or persistent failures can lead to infringement notices, trial suspensions, or legal prosecution. The MHRA emphasizes that sponsors must maintain robust oversight and monitoring mechanisms to ensure all staff and contractors adhere to regulatory requirements.